Epithalon

SIRT6 is described as the most longevity-relevant sirtuin, managing DNA repair and telomere stability — functions that decline with age. The speaker explicitly links SIRT6's mechanism of action to that of Epithalon (pineal gland bioregulator peptide), both activating telomerase. The framing suggests Epithalon is being used as an external substitute for declining endogenous SIRT6 activity. No dosage for Epithalon is provided in this segment.

The speaker discusses telomere attrition as a key hallmark of aging and references bioregulator peptides (specifically Epithalon) as tools that can help maintain telomere caps on chromosomes. Maintaining telomere length is framed as a strategy to preserve the Hayflick limit — the number of times a cell can replicate before senescence. The speaker positions peptide bioregulators as one mechanism to address this hallmark alongside lifestyle interventions.

The speaker references Epithalon as a pineal gland bioregulator, situating it within the broader class of biopeptide regulators discussed on the podcast. It is mentioned in the context of telomerase activation and telomere protection as part of an anti-aging strategy. The speaker implies familiarity with its use among the podcast audience, suggesting it has been covered in prior episodes. No dosage, frequency, or stacking protocol is provided in this transcript.

Epithalon is cited as a known activator of telomerase, the enzyme responsible for maintaining telomere length. The speaker draws a parallel between Epithalon's mechanism and Sirtuin 6 (SIRT6) activation, both of which converge on telomerase activation. The pineal gland bioregulator (Epithalon) is presented as an external agent that achieves what SIRT6 does endogenously. No specific dosage or protocol is mentioned in this context.

During a discussion of the hallmarks of aging, the speaker references bioregulators (including Epithalon by implication as a pineal bioregulator) in the context of telomere attrition — the shortening of protective caps on chromosomes that limits the Hayflick limit of cell replication. The speaker frames bioregulators as tools that can help maintain telomere length and thus extend healthy cellular replication. This is a passing reference rather than a detailed protocol, and no dosing information is provided.

The speaker identifies Epithalon as a pineal gland bioregulator that activates telomerase, placing it within the broader framework of the hallmarks of aging — specifically telomere attrition. The mention is brief and comparative rather than a dedicated protocol discussion. The speaker suggests that endogenous SIRT6 activation could serve a similar function, implying Epithalon is a known reference point for listeners familiar with peptide-based longevity protocols. No dosage or safety data is discussed in this context.

The speaker draws a direct mechanistic parallel between Epithalon (a pineal gland bioregulator peptide) and SIRT6 activation, both of which are described as activating telomerase. The speaker frames Epithalon as an external agent that achieves what the body's own SIRT6 pathway can do internally. This is presented as context for why activating endogenous longevity pathways (via plant compounds) is desirable. No dosage, frequency, or stacking protocol is provided.

The speaker references Epithalon (referred to as 'Epitoolon') as a known activator of telomerase, the enzyme responsible for maintaining telomere length. This is mentioned in the context of comparing it to Sirtuin 6 (SIRT6) activation, which also stimulates telomerase. The speaker implies that activating SIRT6 endogenously could replicate or complement what Epithalon does exogenously. No specific dosage or protocol is mentioned.